Divi's Lab inks supply pact with global pharmaceutical entity
Divi's Laboratories announced a long-term supply agreement with a global pharmaceutical company, focusing on manufacturing and supplying advanced intermediates. The company anticipates significant revenue generation from this partnership.
The company expects meaningful revenue contribution from this long-term agreement, it added without disclosing the identity of the partner.
"The company is planning for capacity addition at its manufacturing facilities with an estimated investment between Rs 650 crore to Rs 700 crore, to be funded from internal accruals," it said.
Shares of the company were trading 2.07 per cent down at Rs 5,638.35 apiece on BSE.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.